Perrigo's revenues jumped with its Elan buyout; Shire bails on Vyvanse as a depression treatment;

@FiercePharma: AbbVie is hit with 5 lawsuits citing the dangers of its 'low T' drug. News | Follow @FiercePharma

@TracyStaton: Perhaps not coincidentally, best-read special report: Top 10 pharma layoffs of 2013. Report | Follow @TracyStaton

@EricPFierce: It is litigation seminar for pharma today. Roche halting Mylan's biosimilar launch, Abbvie sued over AndroGel & more. | Follow @EricPFierce

> Perrigo ($PRGO), which laid out $8.6 billion last year to buy Elan ($ELN) and its low-tax Irish address, reported record earnings. Release

> Shire ($SPHG) has stopped development of its ADHD drug Vyvanse as a treatment for depression after it failed in two late-stage trials. Story

> A congresswoman has told the FDA she thinks its efforts to speed drug approvals is putting patients at risk. Story

> India is looking to issue a compulsory license for Bristol-Myers Squibb's ($BMY) leukemia drug Sprycel. Story

> The FDA says its efforts to fight drug shortages in the U.S. are paying off. Report

Medical Device News

@FierceMedDev: Myriad Genetics' performance and M&A plans produce investor bliss. Story | Follow @FierceMedDev

@MarkHFierce: Scottish startup Edinburgh Molecular Imaging pulled in more than $6.5 million in Series A financing. Release | Follow @MarkHFierce

@MichaelGFierce: Hot on FierceDrugDelivery: Pfizer snags electroporation device license from Ichor for cancer vaccine delivery. News | Follow @MichaelGFierce

@EmilyWFierce: Insulet packing up camp, making room for expansion. Article | Follow @EmilyWFierce

> LabCorp eked out year-end growth while Dx reimbursement problems remained. Report

> Sorin touts a big Q4 earnings boost in preliminary results. More

> FDA: Guidance for medical device interoperability standards is on its way. Item

Biotech News

@FierceBiotech: Biotech VC Clarus reaches for $375M in its latest fund. Story | Follow @FierceBiotech

@JohnCFierce: Martoma guilty in the bapineuzumab insider trading case. Can't say I'm surprised. They had him cold. Story via NYT | Follow @JohnCFierce

@DamianFierce: Biotech IPOs: $500M in a single week should accelerate some R&D efforts. More | Follow @DamianFierce

@EmilyMFierce: Stem cell lines not fit for clinic. Story via The Scientist | Follow @EmilyMFierce

> U.S. rep rips the FDA's efforts to speed up drug approvals. Story

> Despite pomp and circumstance, 2014's looking short on blockbusters. More

And Finally... Germany's Boehringer Ingelheim has become a corporate member of the U.S. Hispanic Chamber of Commerce and will partner with the group to raise awareness of chronic diseases like diabetes. Report